BioPharm International's BP Elements, April 2022

April 13, 2022

Battles against antibiotic-resistant bacteria can be won with bacteriophages.

April 13, 2022

With high-concentration biologics, careful selection of excipients in formulation is crucial for reducing viscosity without destabilizing the protein.

April 08, 2022

Evonetix’s thermally controlled DNA synthesis technology is designed to enable highly parallel DNA synthesis in a benchtop platform.

April 07, 2022

PerkinElmer’s HTRF and AlphaLISA assay kits are designed to detect and quantify CHO host cell protein impurities.

April 07, 2022

The Thermo Scientific Ramina Process Analyzer is designed with user ease at the forefront.

April 05, 2022

Sterling Pharma Solutions has unveiled a £1 million expansion project to increase its capabilities and laboratories capacity at its Deeside, UK site.

April 01, 2022

Thermo Fisher Scientific’s new Gibco CTS Xenon Electroporation System aims to provide easier scale up for cell therapies, from clinical development to commercial manufacturing.

April 01, 2022

Under the two-year task order, ATCC will continue to support the DCEG MEAS program in receiving, processing, storing, analyzing, and distributing clinical specimens from different cancer types.

April 01, 2022

Researchers from the Telomere-to-Telomere Consortium have discovered new properties about junk DNA that could have wide-reaching implications.

March 16, 2022

ProteoGenix’s new XtenCHO Transient Expression can achieve up to ten times higher yields than market-leading CHO systems.

March 15, 2022

Evitria has entered into an agreement with mAbsolve that will allow the company to use mAbsolve’s gene silencing technology in their antibody cells.

March 15, 2022

Flow Eighteeen38 is receiving a €5 million (US$5.58 million) investment from its parent company, FairJourney Biologics.